At steady state, most Rho GTPases are bound in the cytosol to Rho guanine nucleotide dissociation inhibitors (RhoGDIs) 1 . RhoGDIs have generally been considered to hold Rho proteins passively in an inactive state within the cytoplasm. Here we describe an evolutionarily conserved mechanism by which RhoGDI1 controls the homeostasis of Rho proteins in eukaryotic cells. We found that depletion of RhoGDI1 promotes misfolding and degradation of the cytosolic geranylgeranylated pool of Rho GTPases while activating the remaining membranebound fraction. Because RhoGDI1 levels are limiting, and Rho proteins compete for binding to RhoGDI1, overexpression of an exogenous Rho GTPase displaces endogenous Rho proteins bound to RhoGDI1, inducing their degradation and inactivation. These results raise important questions about the conclusions drawn from studies that manipulate Rho protein levels. In many cases the response observed may arise not simply from the overexpression itself but from additional effects on the levels and activity of other Rho GTPases as a result of competition for binding to RhoGDI1; this may require a re-evaluation of previously published studies that rely exclusively on these techniques.
At steady state, most Rho GTPases are bound in the cytosol to Rho guanine nucleotide dissociation inhibitors (RhoGDIs) 1 . RhoGDIs have generally been considered to hold Rho proteins passively in an inactive state within the cytoplasm. Here we describe an evolutionarily conserved mechanism by which RhoGDI1 controls the homeostasis of Rho proteins in eukaryotic cells. We found that depletion of RhoGDI1 promotes misfolding and degradation of the cytosolic geranylgeranylated pool of Rho GTPases while activating the remaining membranebound fraction. Because RhoGDI1 levels are limiting, and Rho proteins compete for binding to RhoGDI1, overexpression of an exogenous Rho GTPase displaces endogenous Rho proteins bound to RhoGDI1, inducing their degradation and inactivation. These results raise important questions about the conclusions drawn from studies that manipulate Rho protein levels. In many cases the response observed may arise not simply from the overexpression itself but from additional effects on the levels and activity of other Rho GTPases as a result of competition for binding to RhoGDI1; this may require a re-evaluation of previously published studies that rely exclusively on these techniques.
The RhoGDI family has been generally relegated to a secondary role in the regulation of Rho GTPases 1 . To explore the function of RhoGDI1, we analysed the effect of depleting RhoGDI1 in mammalian cells. On depletion of RhoGDI1 by short interfering RNA (siRNA), the protein levels of the major Rho GTPases, including RhoA, RhoC, Rac1 and Cdc42, were markedly decreased (Fig. 1a ). This occurred for multiple cell types, including HeLa, fibroblasts, breast epithelial, melanoma and endothelial cells ( Fig. 1a ; Supplementary Information, Fig. S1a-d) . RhoB, which does not bind RhoGDI1, was unaffected by RhoGDI1 silencing ( Fig. 1a ; Supplementary Information, Fig. S2a, b ). The mRNA levels of RhoA, Rac1 and Cdc42 remained constant, suggesting that post-transcriptional mechanisms account for the decrease in Rho proteins (Fig. 1b) . Indeed, proteasomal inhibitors such as LLnL, but not calpain or cathepsin inhibitors, partly rescued Rho proteins from degradation, suggesting that without RhoGDI1 the GTPases are being cleared by the proteasome (Fig. 1c , and data not shown). Rescue from degradation was achieved by expressing an siRNA-resistant RhoGDI1 ( Fig. 1d ; Supplementary Information,  Fig. S2d ). A second independent RhoGDI1 siRNA generated similar effects (data not shown). Interaction between the Rho GTPases and RhoGDI is essential to prevent GTPase degradation, because siRNA-resistant mutants that cannot bind Rho GTPases 2 failed to rescue the effects of RhoGDI1 depletion (Fig. 1d ). Overexpression of wild-type RhoGDI1 but not the GTPase-binding-deficient mutant increased the total levels of RhoA and Rac1 (Fig. 1e ). These results indicate that RhoGDI1 stabilizes Rho proteins, protecting them from degradation.
Even though RhoA, Rac1 and Cdc42 levels were drastically decreased after RhoGDI1 depletion, the amount of active Rho protein was either significantly increased (Rac1 and Cdc42) or unchanged (RhoA) ( Fig. 1f ), which indicates that a much larger fraction of the remaining pool of GTPase is in the active GTP-bound state. Whereas the activity increases by up to twofold, the ratio between active and total GTPase increases by up to tenfold as a result of the decrease in GTPase protein level ( Fig. 1g ). At steady state the active GTPase represented 1% of total RhoA, whereas in the absence of RhoGDI1 it peaked at 10% ( Fig. 1f, g) . After RhoGDI1 depletion, most RhoA is in the membrane fraction, suggesting that most of the degraded protein derives from the cytosolic pool ( Fig. 1h ) and that the active fraction is associated with membranes. In contrast, when an individual GTPase is silenced, both the protein levels and the activity are reduced proportionally (Fig. 1i ). These results highlight the importance of GDI proteins in regulating both the protein level and activation state of Rho GTPases. RhoGDI depletion in other cell types (WM2664 and human umbilical-vein endothelial cells (HUVECs)) caused similar decreases in Rho protein levels ( Supplementary Information, Fig. S1a-d ), whereas the activity of the remaining fraction was either elevated or unchanged ( Fig. 2d ; Supplementary Information, Fig. S1d ). A study of HUVECs also found that RhoGDI knockdown promoted RhoA activation, although Rho protein expression was not decreased as much as observed here, probably because the knockdown was only allowed to proceed for 30 h (ref. 3 ). More complete RhoGDI1 knockdown and Rho GTPase degradation was achieved at longer time intervals ( Supplementary Information, Fig. S1e ).
To determine whether this aspect of RhoGDI function is evolutionarily conserved, we analysed the effect of deleting the single RhoGDI gene in Saccharomyces cerevisiae (RDI1). Strikingly, the loss of Rdi1 protein also resulted in degradation of Cdc42 and Rho1 (RhoA orthologue) while maintaining high levels of activation ( Fig. 1j ). When analysed by immunofluorescence, both Cdc42 and Rho1 had an increase in protein polarized in the bud, which has previously been correlated with localization of the activated forms of these proteins 4, 5 (Fig. 1k , l). The increase in polarized bud staining is striking given the overall decrease in Rho1 and Cdc42 protein levels in rdi1∆ strains.
RhoGDI1 (Arhgdia)-knockout mice are viable but display progressive kidney defects, leading ultimately to death 6 . Those defects have been attributed to increased Rac1 activation, and the kidneys show decreased levels of Rho GTPases 7 . Renal mesangial cells from RhoGDI knockout mice display altered growth and survival 8 . However, RhoGDI1-null mouse fibroblasts showed no defects in the reorganization of the actin cytoskeleton on stimulation with growth factors, or in cell migration measured in a wound-healing assay 6 .
Yeast cells lacking rdi1 have a very minor phenotype 9 . Surprised by the relatively mild phenotype in spite of the marked change in Rho protein levels and activity, we explored this further. Consistent with previous work is our observation that the rate of wound closure was unaffected when RhoGDI1 was knocked down in HeLa cells ( Fig. 2a ). However, the migration velocity of highly motile melanoma cells was significantly decreased on RhoGDI knockdown, both in a woundhealing assay ( Fig. 2b) and when single-cell migration was analysed ( Fig. 2c , f, g; Supplementary Information, Movie S1). This decrease in migration speed was unexpected, given that Rac1 activity was increased ( Fig. 2d ). However, RhoA activity also increased proportionally and may counteract the effects of high Rac1 activity ( Fig. 2d ). Although RhoGDI1 knockdown affected cell migration, we were surprised by the unexpectedly mild phenotype given the striking level of Rho protein activation after RhoGDI1 depletion. Examining whether RhoGDI2 might compensate for the loss of RhoGDI1 we found that, in cells expressing RhoGDI2 (HeLa and HUVECs), RhoGDI2 levels did not vary after RhoGDI1 knockdown (Supplementary Information, Figs S1d and S3c). In WM2664 cells and gingival fibroblasts the expression of RhoGDI2 was undetectable and unaffected by RhoGDI1 silencing ( Supplementary Information, Fig. S3c ). In HeLa cells, silencing GDI1 and GDI2 showed no effect on wound closure speed ( Supplementary  Information, Fig. S3a ), suggesting that the lack of phenotype is not due to a GDI2 compensation effect.
We speculated that, on RhoGDI1 depletion, Rho proteins may fail to localize properly to the plasma membrane and may remain in the endoplasmic reticulum, where the final steps in Rho GTPase maturation occur on the cytoplasmic face of the endoplasmic reticulum. Here they are processed post-translationally after being prenylated in the cytosol 10 . Subcellular fractionation experiments showed that in control cells RhoA, Rac1 and Cdc42 have a biphasic distribution occurring in both the plasma membrane and endoplasmic reticulum fractions (Fig. 2h, i) . However, after RhoGDI1 depletion the amount of Rho GTPases found associated with the plasma membrane was greatly decreased: most of the remaining GTPases co-fractionated with the endoplasmic reticulum ( Fig. 2h, i) . These results show that, without RhoGDI1, Rho proteins that are not degraded are not delivered properly to the plasma membrane; they accumulate instead at the endoplasmic reticulum, suggesting that one function of RhoGDI1 is to shuttle Rho GTPases from the endoplasmic reticulum to their site of action at the plasma membrane. In support of these results, we did not detect an increase in effector activation after GDI1 knockdown, despite the high levels of active GTPases (Fig. 2e) . These results may explain the mild phenotype resulting from RhoGDI1 depletion in spite of high Rho protein activity.
Rho proteins undergo ubiquitylation and degradation by the proteasome after irreversible activation by the bacterial toxin CNF1 (ref. 11). Because RhoGDI1 knockdown promoted a substantial activation of Rho proteins, we explored whether degradation occurred similarly, after activation. To inhibit activation of RhoA we either overexpressed the RhoA-specific GAP, p190-RhoGAP, or incubated cells with C3 transferase, which inactivates RhoA, and then monitored its degradation after GDI1 silencing. Both treatments decreased RhoA activity to negligible amounts (Fig. 3a, b ). However, degradation of RhoA after GDI1 depletion still occurred, indicating that this is independent of RhoA activation (Fig. 3a, b) .
Our results suggest that binding to RhoGDI1 stabilizes and protects Rho GTPases from degradation, and that a GTPase that is not bound to a GDI protein or associated with the membrane is rapidly degraded. Most Rho proteins (RhoA, Rac1 and Cdc42) are modified post-translationally at the carboxyl terminus with a geranylgeranyl group 12 . General prenylation inhibitors from the statin family, such as lovastatin, or geranylgeranyl transferase specific inhibitors such as GGTI2417, rescued the degradation of GTPases in the absence of GDI (Fig. 3c , and data not shown). Similarly, cleavage of the geranylgeranylated C-terminal tail using the bacterial protease YopT 13 also restored RhoA levels, indicating that newly synthesized Rho proteins are prenylated and fully mature before being degraded and that removing the prenylation is sufficient to stabilize Rho GTPases (Fig. 3d ). Treatment with GGTI2417 restores the cytosolic pool of RhoA in the absence of RhoGDI1, suggesting that a Rho GTPase can only exist in the cytosol if it is either bound to RhoGDI1 or not prenylated ( Supplementary Information, Fig. S4 ). We speculated that, without the RhoGDI1 to protect the prenyl group, this exposed hydrophobic modification might disturb the correct folding of Rho proteins, targeting them for degradation. In cells, proper protein folding is ensured by molecular chaperones 14 . Proteins that cannot fold properly usually cluster in insoluble aggregates that are targeted for degradation 14 . We found that, under physiological conditions, RhoA associates with the molecular chaperone Hsp70 (Fig. 3e ). In the absence of RhoGDI1, the levels of Hsp70 increased in cells, which was indicative of a cellular stress, but virtually no Hsp70 was bound to RhoA, suggesting that the remaining membrane-bound RhoA is properly folded and stable (Fig. 3e) . Indeed, Hsp70 bound mostly to cytosolic RhoA (Fig. 3f) . When we inhibited the proteasome in RhoGDI1-depleted cells, RhoA and Rac1 accumulated in a Triton-insoluble fraction (data not shown). The amount of Hsp70 bound to cytosolic RhoA also increased, suggesting that the pool of free prenylated RhoA was misfolded or partly unfolded and therefore recruited the protein quality control machinery (Fig. 3f) . These results suggest that prenylation contributes to the misfolding or unfolding of Rho proteins, resulting in their degradation if RhoGDI1 cannot accommodate the lipid moiety and if the molecular chaperones cannot fold them properly. Although RhoA co-precipitates with both Hsp70 and RhoGDI1 (Fig. 3e) , immunoprecipitation of RhoGDI1 indicates that there are two mutually exclusive pools of RhoA associated with either Hsp70 or RhoGDI1 ( Supplementary Information, Fig. S2a ). Finally, inhibiting molecular chaperones with geldanamycin decreased RhoA levels in the presence or absence of RhoGDI1, arguing that molecular chaperones are required to help stabilize prenylated RhoA (Fig. 3g) .
In mammalian cells, the level of RhoGDI1 is roughly equivalent to the total levels of RhoA, Rac1 and Cdc42 combined 15 . A competitive balance therefore exists between Rho proteins for binding to RhoGDI1, and any condition that alters the level of one GTPase should disrupt this balance and affect Rho protein homeostasis. Figure 4a shows that silencing RhoA results in decreased levels of RhoA and proportionally increased levels of Rac1 and Cdc42, indicating that decreasing one GTPase generates free GDI that can be shared by the others. In contrast, overexpression of Myc-tagged RhoA, Rac1 or Cdc42 displaced endogenous RhoA from RhoGDI1 (Fig. 4b ). Overexpression of a Myc-tagged Cdc42 mutant (R66E) incapable of binding RhoGDI did not affect the level of endogenous RhoA (Fig. 4c) . The displacement of endogenous Rho proteins resulted in their degradation in a dose-dependent manner (Fig. 4d, g, j) . Strikingly, expression of constitutively active (Fig. 4e, h, k) or dominant-negative ( Fig. 4f , i, l) Rho proteins also displaced endogenous Rho proteins from RhoGDI1 and caused their degradation. The degradation of RhoA by overexpression of Cdc42 could be prevented by co-expression of RhoGDI1 (Fig. 4m ). Displacement of Rho proteins from RhoGDI1 by other Rho family members, including RhoA, Rac1 and Cdc42, resulted in their degradation and inactivation ( Fig. 4n-p) . This degradation and inactivation did not occur if the overexpressed Rho protein was a mutant (RhoA R68E, Rac1 R66E or Cdc42 R66E) unable to bind RhoGDI1 ( Fig. 4n-p) . The decrease in activity of Rho GTPases displaced from RhoGDI1 is similar to that observed when GTPases are silenced by RNA-mediated interference (RNAi) (Fig. 1i ), and contrasts with the activation of Rho GTPases caused by RhoGDI1 depletion.
One might expect that depletion of RhoGDI1 and competitive displacement of Rho GTPases from RhoGDI1 would have the same effect on Rho protein activity, given that both result in the degradation of Rho GTPases. However, in the case of overexpression of an exogenous Rho GTPase, RhoGDI1 is still present and over time will extract and inactivate the remaining endogenous GTPases from the membrane. Competitive displacement of endogenous Rho proteins from RhoGDI1 by overexpressed Rho GTPases will release the endogenous Rho proteins into the cytosol; they will subsequently be degraded without the opportunity for activation. In contrast, during RhoGDI1 depletion, Rho proteins associated with membrane cannot be actively extracted by RhoGDI. These membrane-bound Rho GTPases are likely to become activated by membrane-bound guanine nucleotide-exchange factors. Because RhoGDI1 can inhibit both the activation of the Rho GTPases and also GTP hydrolysis 16, 17 , depletion of RhoGDI1 should relieve this inhibition, thereby promoting activation of the GTPases. In contrast, displacement of Rho proteins from GDI does not alter the cellular content of RhoGDI1, Figure 5 RhoGDI regulates Rho protein homeostasis. Newly synthesized RhoGTPases are geranylgeranylated and post-translationally modified in the endoplasmic reticulum (ER). After geranylgeranylation, Rho proteins associate directly with RhoGDI, which sequesters them as a soluble prenylated form in the cytosol and protects them from degradation. On depletion of RhoGDI1 or overexpression of Rho proteins, endogenous RhoGTPases are released to the cytosol, where they exist as short-lived unstable intermediates that are partly folded or misfolded (red arrows). These can bind to the chaperone complex or be targeted for degradation if they are unable to fold properly. In the absence of GDI, newly synthesized Rho proteins cannot be delivered to the plasma membrane (PM) and accumulate in the endoplasmic reticulum. At steady state, this unstable intermediate is not detected and RhoGTPases are for the most part either associated with cell membranes or bound to GDI, with only a small fraction being associated with the chaperone system. GGTase, geranylgeranyl transferase; Rce1, prenyl-protein specific protease; Icmt, isoprenylcysteine carboxyl methyltransferase. maintaining this inhibitory mechanism on endogenous GTPases. Indeed, we show that after RhoGDI1 depletion, the remaining RhoA that is not targeted for degradation is not bound to GDI (Fig. 3e ). Furthermore, our results demonstrate that depletion of RhoA either by direct silencing or by overexpressing an exogenous GTPase results in a decrease in both total and active RhoA, whereas RhoGDI silencing decreases RhoA levels but leaves RhoA activity high (Figs 1i and 4o, p) .
We have shown that RhoGDI1 regulates the stability of Rho GTPases within the cytosol, protecting them from degradation. Our results also reveal an unexpected crosstalk between Rho GTPases through competitive binding to RhoGDI1, illustrated schematically in Fig. 5 . Rather little is known about changes in expression levels of RhoGDI1 or Rho GTPases during development and disease, although situations have been described in which the expression of a Rho family member occurs, such as the increase of RhoC in metastasis 18 . In preliminary work we have found that with different breast cancer cell lines the expression of RhoGDI1 correlates with their invasiveness and also with the level and activity of RhoA and Rac1 ( Supplementary Information, Fig. S5 ). However, in situations where the level of RhoGDI stays constant, our results predict that not only does overexpressing one GTPase displace the others from RhoGDI and target them for degradation but it also affects their activity. One situation in which extreme changes occur is in the experimental expression of wild-type or mutant Rho GTPases, which have been the standard tools for the study of Rho protein functions in different pathways. In many cases, the conclusions drawn from these studies may arise not only from the activity of the overexpressed Rho protein but also from the unexpected effect of displacing other family members from RhoGDI, leading to their degradation and inactivation. 
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